Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Details Textual)

v2.4.0.8
Summary of Significant Accounting Policies (Details Textual) (USD $)
12 Months Ended 101 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2013
Sep. 21, 2012
Summary Of Significant Accounting Policies [Line Items]        
Research and Development Expense $ 879,886 $ 1,012,144 $ 5,449,678  
Deferred Setup and Organization Costs, Amortization Period (in months) 180 months      
Deferred Setup and Organization Costs, Amortization Period (in Years) 20 years      
Clinical Research And Development Cost Percentage 32.00% 16.00%    
Fees For Services Total 14,964 163,661    
Agreement With Theradex Systems [Member]
       
Summary Of Significant Accounting Policies [Line Items]        
Annual Fee Payable, Clinical Trial       2,000,000
Clinical Cost Charged To Operations Total 278,721      
Clinical Research And Development Cost Percentage 2.00%      
Fees For Services Total 14,964 163,661 194,551  
Patents [Member]
       
Summary Of Significant Accounting Policies [Line Items]        
Research and Development Expense $ 405,285 $ 236,784 $ 1,814,682